SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development
en-GBde-DEes-ESfr-FR

SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development

05/08/2022 Compuscript Ltd

https://doi.org/10.1016/j.bsheal.2021.07.003

The present pandemic has posed a crisis to the economy of the world and the health sector. Therefore, the race to expand research to understand some good molecular targets for vaccine and therapeutic development for SARS-CoV-2 is inevitable.

The newly discovered coronavirus 2019 (COVID-19) is a positive sense, single-stranded RNA, and enveloped virus, assigned to the beta CoV genus. The virus (SARS-CoV-2) is more infectious than the previously detected coronaviruses (MERS and SARS). Findings from many studies have revealed that S protein and RdRp are good targets for drug repositioning, novel therapeutic development (antibodies and small molecule drugs), and vaccine discovery. Therapeutics such as chloroquine, convalescent plasma, monoclonal antibodies, spike binding peptides, and small molecules could alter the ability of S protein to bind to the ACE-2 receptor, and drugs such as remdesivir (targeting SARS-CoV-2 RdRp), favipir, and emetine could prevent SASR-CoV-2 RNA synthesis. The novel vaccines such as mRNA1273 (Moderna), 3LNP-mRNAs (Pfizer/BioNTech), and ChAdOx1-S (University of Oxford/Astra Zeneca) targeting S protein have proven to be effective in combating the present pandemic.

Further exploration of the potential of S protein and RdRp is crucial in fighting the present pandemic.

Keywords: SARS-CoV-2, Spike protein (S protein), RNA dependent RNA polymerase (RdRp), Drug repositioning, SARS-CoV-2-vaccines
# # # # # #
Biosafety and Health is sponsored by the Chinese Medical Association, managed by National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC).
For more information, please visit https://www.journals.elsevier.com/biosafety-and-health
Editorial Board: https://www.sciencedirect.com/journal/biosafety-and-health/about/editorial-board

Biosafety and Health is available on ScienceDirect (https://www.sciencedirect.com/journal/biosafety-and-health).

Submissions to Biosafety and Health may be made using Editorial Manager® (https://www.editorialmanager.com/bsheal/default.aspx).

CiteScore:4.8

ISSN 2590-0536

# # # # # #

Article reference: Yusuf Muhammed, Abduljalal Yusuf Nadabo, Mkpouto Pius, Bashiru Sani, Jafar Usman, Nasir Anka Garba, Jaafaru Mohammed Sani, Basit Opeyemi Olayanju, Sunday Zeal Bala, Musa Garba Abdullahi, Misbahu Sambo, SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review, Biosafety and Health, Volume 3, Issue 5, 2021, Pages 249-263, ISSN 2590-0536, https://doi.org/10.1016/j.bsheal.2021.07.003
Yusuf Muhammed, Abduljalal Yusuf Nadabo, Mkpouto Pius, Bashiru Sani, Jafar Usman, Nasir Anka Garba, Jaafaru Mohammed Sani, Basit Opeyemi Olayanju, Sunday Zeal Bala, Musa Garba Abdullahi, Misbahu Sambo, SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review, Biosafety and Health, Volume 3, Issue 5, 2021, Pages 249-263, ISSN 2590-0536, https://doi.org/10.1016/j.bsheal.2021.07.003
05/08/2022 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Covid-19, Covid-19

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2022 by AlphaGalileo Terms Of Use Privacy Statement